Regulatory Disclosure Summary

Details of the Tax Order

  • Order Date: May 21, 2026
  • Date of Receipt: May 22, 2026, at 8:42 AM (IST)
  • Assessment Year: FY 2022-23
  • Quantum of Tax Adjustments: ₹107.89 crores
  • Primary Basis: Transfer pricing adjustments
  • Opposing Party: Income Tax Department

Company's Response and Legal Position

Jubilant Generics Limited believes the tax adjustments were made ignoring the facts and contentions presented by the company. Accordingly, the company is:

  • In the process of filing an appeal before the Commissioner of Income Tax (Appeals) against the impugned order
  • Has separately filed an application before the Advance Pricing Authority covering the year under consideration

Financial Implications

  • Immediate Impact: Reduction in Deferred Tax Assets to the extent of ₹37.70 crores
  • Expected Outcome: The company expects to receive relief from the relevant Appellate Authority and/or Advance Pricing Authority
  • Overall Assessment: Jubilant Generics Limited does not anticipate any material financial implications post-adjudication or redressal process

Additional Information

The document was simultaneously posted on the company's website at www.jubilantpharmova.com. The disclosure was signed by Naresh Kapoor, Company Secretary of Jubilant Pharmova Limited, on May 22, 2026, at 19:36:15 IST.